ArticleBMJ oncology2023
Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort study.
Article in BMJ oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04063566 (ReIMAGINE Prostate Cancer Screening - Inviting Men for Prostate Cancer Screening Using MRI), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ReIMAGINE Prostate Cancer Screening - Inviting Men for Prostate Cancer Screening Using MRI
Who cites it
15 citing papers in PubMed.
- Critical appraisal of artificial intelligence studies for prostate cancer detection on MRI.European radiology · 2026Article
- The value of micro-ultrasound for prostate cancer screening: A retrospective real-world feasibility study.Prostate cancer and prostatic diseases · 2026Article
- Ongoing and completed clinical trials on prostate cancer screening using MRI.European radiology · 2026Review
- Diagnostic accuracy of a 'stage-gated' approach for reporting prostate screening MRI: "Is less more?"European radiology · 2026Article
- Artificial Intelligence in Prostate MRI: Addressing Current Limitations Through Emerging Technologies.Journal of magnetic resonance imaging : JMRI · 2026Review
- Diagnostic accuracy of abbreviated biparametric MRI for prostate cancer screening: a prospective feasibility study (ReIMAGINE study).European radiology · 2026Article
- Prostate cancer screening.Asian journal of urology · 2025Review
- Emerging tools for the early detection of prostate cancer.BJUI compass · 2025Review
- Use of a BMI-independent biomarker-based prostate cancer risk score to identify and triage individuals at risk of prostate disease.Scientific reports · 2025Article
- ProstaPilot: A Comparative Study of Biparametric Magnetic Resonance Imaging Versus Prostate-specific Antigen as a Screening Test for Prostate Cancer.European urology open science · 2025Article
- Characterisation of Multiparametric Magnetic Resonance Imaging of the Prostate in Younger Men with Normal Prostate-specific Antigen Within the PROBASE Study.European urology open science · 2025Article
- Assessment of a Polygenic Risk Score in Screening for Prostate Cancer.The New England journal of medicine · 2025Observational
- Measuring and improving the cradle-to-grave environmental performance of urological procedures.Nature reviews. Urology · 2025Review
- Understanding prostate cancer care: recent progress and future direction.BMJ oncology · 2025Article
- Targeted Prostate Health Checks, a novel system to identify men with prostate cancer-A pilot study.BJUI compass · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In men with a raised prostate-specific antigen (PSA), MRI increases the detection of clinically significant cancer and reduces overdiagnosis, with fewer biopsies. MRI as a screening tool has not been assessed independently of PSA in a formal screening study. We report a systematic community-based assessment of the prevalence of prostate MRI lesions in an age-selected population. Methods and analysis: Men aged 50-75 were identified from participating general practice (GP) practices and randomly selected for invitation to a screening MRI and PSA. Men with a positive MRI or a raised PSA density (≥0.12 ng/mL Results: Eight GP practices sent invitations to 2096 men. 457 men (22%) responded and 303 completed both screening tests. Older white men were most likely to respond to the invitation, with black men having 20% of the acceptance rate of white men.One in six men (48/303 men, 16%) had a positive screening MRI, and an additional 1 in 20 men (16/303, 5%) had a raised PSA density alone. After NHS assessment, 29 men (9.6%) were diagnosed with clinically significant cancer and 3 men (1%) with clinically insignificant cancer.Two in three men with a positive MRI, and more than half of men with clinically significant disease had a PSA <3 ng/mL. Conclusions: Prostate MRI may have value in screening independently of PSA. These data will allow modelling of the use of MRI as a primary screening tool to inform larger prostate cancer screening studies. Trial registration number: NCT04063566.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.